Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021
Zejing pharmaceutical announced its annual performance loss forecast for 2021. The company expects a net loss of 372 million yuan to 455 million yuan in 2021. During the reporting period, the company was in the early stage of drug commercialization and needed to invest more in early stage market development and academic promotion activities; At the same time, the company's new drug R & D pipeline is further enriched, and several innovative drugs are in key clinical trials. It is estimated that the R & D cost in 2021 will be about 472 million yuan.
This text is a result of machine translation.
Related companies：
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Briefing May 21, 2022 06:44 AM
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Jan 30, 2026 06:00 PM
Dec 11, 2023 08:49 PM
May 11, 2023 05:07 PM
Nov 16, 2022 05:19 PM
Briefing May 20, 2022 04:58 AM
· Healthcare
Several new funds have actively picked up chips to speed up the pace of position building
Briefing May 10, 2022 04:20 PM
· Healthcare
Nintendo expects profit to fall by 29% this fiscal year and switch sales to 21 million units
Technology · Interview
Exclusive Interview: NAVEE GOLF Is Building a Smart Golf Ecosystem, Starting with Push Carts
In an interview with EqualOcean, Wentao Shi, Head of NAVEE GOLF, discussed the company's strategic rationale for entering the golf industry, explained how it adapted its mobility and robotics technologies for golf courses, and elaborated on why user insights had become the key differentiator in global markets.
Yesterday 05:04 PM
Briefing Apr 18, 2022 10:18 PM
· Technology
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
Technology, Consumer Staples, Mobility
Unpacking China | Key Chinese Firms to Watch This Week （05/04/2026-11/04/2026）
Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.
Apr 10, 2026 05:02 PM
Healthcare
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Briefing Feb 07, 2022 06:49 PM
· Healthcare
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
See more
Read next
Insight
In-depth
Technology · Interview
Exclusive Interview: NAVEE GOLF Is Building a Smart Golf Ecosystem, Starting with Push Carts
Yesterday 05:04 PM
Insight
In-depth
Embodied AI · Analysis
Chinese Embodied AI Company AI² Robotics: The Real Bottleneck in Embodied AI Is Scenarios, Not Just AI
Apr 14, 2026 11:25 AM
Insight
In-depth
Technology, Embodied AI · Analysis
From 0 to 2.6 million units, Ecovacs Window Robot makes "first choice" the only answer.
Apr 10, 2026 07:00 PM
Insight
In-depth